BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pifeltro (Doravirine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pifeltro (Doravirine)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04892654-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT04892654)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: Efficacy of Dora
 virine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therap
 y Switch\nEstimated primary completion: 30 November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/doravirine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04892654
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774872-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT06774872)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Doravirine/Lamiv
 udine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamiv
 udine (DTG/3TC) in PLWH Successfully\nEstimated primary completion: 15 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doravirine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 74872
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075146-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT07075146)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: DOR/TDF/3TC COmp
 ared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight 
 or Obesity\nEstimated primary completion: 5 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/doravirine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07075146
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203132-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT06203132)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: DORAvirine Versu
 s DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Li
 ving With HIV-1 Infection\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/doravirine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06203132
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871552-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT07871552)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Effects of Switc
 h to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomark
 ers of Aging Among Virologically Suppressed People With HIV\nEstimated pri
 mary completion: 15 April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/doravirine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07871552
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357584-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pifeltro (Doravirine): Phase 4 readout est. (NCT07357584)
DESCRIPTION:Pifeltro (Doravirine)\, phase 4\, HIV.\nStudy: Efficacy and Saf
 ety of Doravirine in the Rapid Initiation\nEstimated primary completion: 3
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doravir
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07357584
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05630638-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pifeltro (Doravirine): Phase 4 readout est. (NCT05630638)
DESCRIPTION:Pifeltro (Doravirine)\, phase 4\, HIV.\nStudy: Doravirine Dose 
 Optimisation in Pregnancy\nEstimated primary completion: July 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/doravirine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05630638
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375800-960@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281112
DTEND;VALUE=DATE:20281113
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT04375800)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Doravirine (DOR)
  in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <
 12 Years and <45 kg (MK-1439-066)\nEstimated primary completion: 12 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/doravirine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04375
 800
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
